Percutaneous cholecystostomy as a definitive treatment for moderate and severe acute acalculous cholecystitis: a retrospective observational study

Table 3 Comparison of the nondeath and death groups

Features	Nondeath (n = 27)	Death (n = 17)	Univariate analysis P-value	Multivariate analysis OR(95% CI) P-value
Sex [Male (%)]	17 (62.9%)	11 (64.7%)	0.91
Age (years)	76 (64–82)	74 (70–80)	0.84
Length of stay	15 (10–26)	14 (8–32)	0.98
TG18 grade
II	12 (44.4%)	6 (35.3%)	0.55
III	15 (55.6%)	11 (64.7%)
aCCI	4 (3–5)	7 (5–9)	0.0010	1.53 (1.08–2.17) 0.018
Preoperative body temperature (℃)	38.0 (36.9–39.0)	38.3 (37.3–39.3)	0.41
Initial laboratory values
Platelets (× 10⁹ L)	172.0 (111.0–290.0)	249.0 (124.5–374.5)	0.21
White blood cells (× 10⁹ L)	9.32 (6.41–16.04)	10.66 (7.65–17.08)	0.56
Neutrophil granulocyte (%)	82.4 (74.3–92.6)	83.4 (81.0–93.0)	0.32
ALT (U/L)	38.0 (23.3–92.0)	22.0 (13.3–34.0)	0.014
STB (μmol/L)	20.0 (13.4–31.1)	17.3 (12.1–32.9)	0.96
CB (μmol/L)	1.4 (0–8.0)	2.9 (0–13.3)	0.69
UCB (μmol/L)	7.8 (3.9–15.5)	6.3 (2.4–12.5)	0.56
Clinical effectiveness	21 (77.8%)	11 (64.7%)	0.55

aCCI age-adjusted Charlson comorbidity index; WBC White blood cells; ALT alanine aminotransferase; STB serum total bilirubin; CB conjugated bilirubin; UCB unconjugated bilirubin

ISSN: 1471-2482